The agency published its annual report estimating drug-related emergency department visits in December.
The data from the report is drawn from the Drug Abuse Warning Network, a surveillance system that captures data from 53 participating hospitals. SAMHSA uses data from these hospitals to generate national estimates.
- There were an estimated 7.6 million drug-related ED visits in the US in 2023, a rate of 2,266 per 100,000 individuals.
- Rates of drug-related emergency department visits were highest among males, at 2,668 per 100,000 individuals, and among non-Hispanic or Latino individuals, at 2,391 per 100,000.
- Around two in three drug-related emergency department visits were individuals aged 26 to 64.
- Alcohol, cannabis and opioids were the most prevalent substances in drug-related emergency department visits in 2023. Alcohol was the most prevalent substance, involved in four in 10 drug-related emergency department visits.
- Alcohol-related visits decreased by 3.6% between 2022 and 2023, and opioid-related visits decreased by 3.7% compared to 2022. Cannabis-related visits increased by 4.6%.
- From 2022 to 2023, opioid-related emergency department visits involving fentanyl increased by 46%, while visits involving heroin decreased by 41%.
- About one in five drug-related ED visits in 2023 involved more than one substance.
Read the full report here.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
